{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:10:21Z","timestamp":1785859821778,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Department of Anesthesiology, General Hospital of Southern Theater Command of People\u2019s Liberation Army"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04522-2","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:34:39Z","timestamp":1771882479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CXCL1 as a novel prognostic biomarker and immune regulator in colon adenocarcinoma"],"prefix":"10.1007","volume":"17","author":[{"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"3","key":"4522_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4522_CR2","doi-asserted-by":"publisher","unstructured":"Fadlallah H, El Masri J, Fakhereddine H, Youssef J, Chemaly C, Doughan S et al. Colorectal cancer: Recent advances in management and treatment. (2218-4333 (Print)). https:\/\/doi.org\/10.5306\/wjco.v15.i9.1136","DOI":"10.5306\/wjco.v15.i9.1136"},{"issue":"1","key":"4522_CR3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","volume":"9","author":"Q Li","year":"2024","unstructured":"Li Q, Geng S, Luo H, Wang W, Mo Y-Q, Luo Q, et al. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy. Signal Transduct Target Therapy. 2024;9(1):266.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"4522_CR4","doi-asserted-by":"publisher","first-page":"7834","DOI":"10.1038\/s41467-025-63200-z","volume":"16","author":"X Guan","year":"2025","unstructured":"Guan X, Zhang Y, Sun R, Wang G, Bi X, Zhang Z, et al. Lymph nodes molecular subtypes unravel lymph nodes heterogeneity and clinical implications in colorectal cancer. Nat Commun. 2025;16(1):7834.","journal-title":"Nat Commun"},{"key":"4522_CR5","doi-asserted-by":"publisher","unstructured":"Khan MN, Mao B, Hu J, Shi M, Wang S, Rehman AU et al. Tumor-associated macrophages and CD8+ T cells: dual players in the pathogenesis of HBV-related HCC. (1664-3224 (Electronic)). https:\/\/doi.org\/10.3389\/fimmu.2024.1472430","DOI":"10.3389\/fimmu.2024.1472430"},{"key":"4522_CR6","doi-asserted-by":"publisher","unstructured":"Xavier H, Gireesh AGM, Thomas JA, Suboj P, Suresh A, Biju E et al. Chemokines: humble yet mighty players in the tumour microenvironment. (1664-3224 (Electronic)). https:\/\/doi.org\/10.3389\/fimmu.2025.1601756","DOI":"10.3389\/fimmu.2025.1601756"},{"key":"4522_CR7","doi-asserted-by":"publisher","unstructured":"Hou CH, Chen PC, Liu JF. CXCL1 enhances COX-II expression in rheumatoid arthritis synovial fibroblasts by CXCR2, PLC, PKC, and NF-\u03baB signal pathway. (1878-1705 (Electronic)). https:\/\/doi.org\/10.1016\/j.intimp.2023.110909","DOI":"10.1016\/j.intimp.2023.110909"},{"key":"4522_CR8","doi-asserted-by":"publisher","unstructured":"Wang HA-O, Chen W, Lie C, Zhang Y, Li J, Meng J et al. ARG1 and CXCL2 are potential biomarkers target for psoriasis patients. (1744-8069 (Electronic)). https:\/\/doi.org\/10.1177\/17448069221128423","DOI":"10.1177\/17448069221128423"},{"key":"4522_CR9","unstructured":"Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. (0741-5400 (Print))."},{"key":"4522_CR10","doi-asserted-by":"publisher","first-page":"115697","DOI":"10.1016\/j.addr.2025.115697","volume":"226","author":"D Srinivasan","year":"2025","unstructured":"Srinivasan D, Gout J, Kleger A, Roger E. Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies. Adv Drug Deliv Rev. 2025;226:115697.","journal-title":"Adv Drug Deliv Rev"},{"key":"4522_CR11","unstructured":"Miyake M, Hori S, Morizawa Y, Tatsumi Y, Nakai Y, Anai S et al. CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. (1476\u20135586 (Electronic))."},{"issue":"1","key":"4522_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","volume":"29","author":"K Kohli","year":"2022","unstructured":"Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29(1):10\u201321.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"4522_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He S, Zheng L, Qi C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol Cancer. 2025;24(1):5.","journal-title":"Mol Cancer"},{"issue":"10","key":"4522_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.neo.2016.08.002","volume":"18","author":"M Miyake","year":"2016","unstructured":"Miyake M, Hori S, Morizawa Y, Tatsumi Y, Nakai Y, Anai S, et al. CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. Neoplasia. 2016;18(10):636\u201346.","journal-title":"Neoplasia"},{"issue":"1","key":"4522_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-025-03765-3","volume":"25","author":"Y Lv","year":"2025","unstructured":"Lv Y, Chen C, Han M, Tian C, Song F, Feng S, et al. CXCL2: a key player in the tumor microenvironment and inflammatory diseases. Cancer Cell Int. 2025;25(1):133.","journal-title":"Cancer Cell Int"},{"key":"4522_CR16","doi-asserted-by":"publisher","unstructured":"Korbecki JA-O, Bosiacki M, Barczak KA-OX, \u0141agocka R, Chlubek DA-O, Baranowska-Bosiacka I. The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers. LID - 10.3390\/cells12101406. LID - 1406. (2073-4409 (Electronic)). https:\/\/doi.org\/10.3390\/cells12101406","DOI":"10.3390\/cells12101406"},{"key":"4522_CR17","doi-asserted-by":"publisher","unstructured":"Cheng J, Chen N, Yin Q, Zheng Z, Chen X, Zhu X et al. Membraneless organelles-based integrative analysis constructs an immune-related prognostic signature and identifies NRG1 as a novel methylation biomarker in colorectal cancer. (1664-3224 (Electronic)). https:\/\/doi.org\/10.3389\/fimmu.2025.1678096","DOI":"10.3389\/fimmu.2025.1678096"},{"key":"4522_CR18","doi-asserted-by":"publisher","unstructured":"Tomczak K, Czerwi\u0144ska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. (1428-2526 (Print)). https:\/\/doi.org\/10.5114\/wo.2014.47136","DOI":"10.5114\/wo.2014.47136"},{"key":"4522_CR19","unstructured":"Edwards Nj Fau -, Oberti M, Oberti M, Thangudu RR, Cai S, McGarvey P, Fau - Jacob S, Jacob S et al. The CPTAC Data Portal: A Resource for Cancer Proteomics Research. (1535-3907 (Electronic))."},{"key":"4522_CR20","unstructured":"Dudley WN, Wickham R, Coombs N. An Introduction to Survival Statistics: Kaplan-Meier Analysis. (2150-0878 (Print))."},{"key":"4522_CR21","doi-asserted-by":"publisher","unstructured":"Warde-Farley D, Donaldson Sl Fau - Comes O, Comes O, Fau - Zuberi K, Zuberi K, Fau - Badrawi R, Badrawi R, Fau - Chao P, Chao P, Fau - Franz M et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. (1362-4962 (Electronic)). https:\/\/doi.org\/10.1093\/nar\/gkq537","DOI":"10.1093\/nar\/gkq537"},{"key":"4522_CR22","unstructured":"Cerami E, Gao J, Fau - Dogrusoz U, Dogrusoz U, Fau - Gross BE. Gross Be Fau - Sumer SO, Sumer So Fau - Aksoy BA, Aksoy Ba Fau - Jacobsen A, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. (2159-8290 (Electronic))."},{"key":"4522_CR23","doi-asserted-by":"publisher","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. (1362-4962 (Electronic)). https:\/\/doi.org\/10.1093\/nar\/gkaa407","DOI":"10.1093\/nar\/gkaa407"},{"key":"4522_CR24","doi-asserted-by":"publisher","unstructured":"Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC et al. TISIDB: an integrated repository portal for tumor-immune system interactions. (1367-4811 (Electronic)). https:\/\/doi.org\/10.1093\/bioinformatics\/btz210","DOI":"10.1093\/bioinformatics\/btz210"},{"key":"4522_CR25","doi-asserted-by":"publisher","unstructured":"Khan MN, Binli M, Juan H, Mengjia S, Shunyao W, Li X. AKR1B10 as a novel prognostic biomarker linking methylation and immune escape in hepatocellular carcinoma. (2730-6011 (Electronic)). https:\/\/doi.org\/10.1007\/s12672-025-03017-w","DOI":"10.1007\/s12672-025-03017-w"},{"key":"4522_CR26","doi-asserted-by":"publisher","unstructured":"Liu CA-O, Hu FA-O, Xie GA-O, Miao YA-O, Li XW, Zeng Y et al. GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. LID - bbac558 [pii] LID - https:\/\/doi.org\/10.1093\/bib\/bbac558. (1477-4054 (Electronic)).","DOI":"10.1093\/bib\/bbac558"},{"key":"4522_CR27","doi-asserted-by":"publisher","unstructured":"Cheng J, Zhang C, Luo Y, Chen Y, Chen N, Wan Y et al. Cell-cycle-related transcriptional factor DLX4: a novel prognostic biomarker and potential therapeutic target in colorectal cancer. (1475-2867 (Print)). https:\/\/doi.org\/10.1186\/s12935-025-03998-2","DOI":"10.1186\/s12935-025-03998-2"},{"key":"4522_CR28","doi-asserted-by":"publisher","unstructured":"Wu JA-O, Zhang L, Kuchi A, Otohinoyi DA-O, Hicks C. CpG Site-Based Signature Predicts Survival of Colorectal Cancer. LID - 10.3390\/biomedicines10123163. LID - 3163. (2227-9059 (Print)). https:\/\/doi.org\/10.3390\/biomedicines10123163","DOI":"10.3390\/biomedicines10123163"},{"key":"4522_CR29","doi-asserted-by":"publisher","unstructured":"Grant G, Ferrer CM. The role of the immune tumor microenvironment in shaping metastatic dissemination, dormancy, and outgrowth. Trends Cell Biol. 2025. https:\/\/doi.org\/10.1016\/j.tcb.2025.05.006","DOI":"10.1016\/j.tcb.2025.05.006"},{"key":"4522_CR30","doi-asserted-by":"crossref","unstructured":"He S, Ma F, Yu M, Wu J-m, Gong Y-m, Luo K-w et al. Neutrophil-mediated immune dysregulation in recurrent miscarriage: implications of APP\u2013CD74 signaling and CXCL1 as diagnostic biomarkers. Frontiers in Immunology. 2025;Volume 16 - 2025.","DOI":"10.3389\/fimmu.2025.1707497"},{"key":"4522_CR31","doi-asserted-by":"publisher","unstructured":"Deng Y, Shi M, Yi L, Naveed Khan M, Xia Z, Li X. Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment. (2405-8440 (Print)). https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37060","DOI":"10.1016\/j.heliyon.2024.e37060"},{"key":"4522_CR32","doi-asserted-by":"publisher","unstructured":"Christopher BA-O, Golick LA-O, Basar A, Reyes L, Robinson RM, Angerstein AA-O et al. Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer. LID - 10.3390\/biom15050645. LID - 645. (2218-273X (Electronic)). https:\/\/doi.org\/10.3390\/biom15050645","DOI":"10.3390\/biom15050645"},{"key":"4522_CR33","doi-asserted-by":"publisher","unstructured":"Korbecki JA-O, Bosiacki MA-O, Pilarczyk M, Kot M, Defort PA-O, Walaszek I et al. The CXCL1-CXCR2 Axis as a Component of Therapy Resistance, a Source of Side Effects in Cancer Treatment, and a Therapeutic Target. LID - 10.3390\/cancers17101674. LID - 1674. (2072-6694 (Print)). https:\/\/doi.org\/10.3390\/cancers17101674","DOI":"10.3390\/cancers17101674"},{"key":"4522_CR34","doi-asserted-by":"publisher","unstructured":"Paradis P, Schiffrin EL. CXCL1-CXCR2 lead monocytes to the heart of the matter. (1522-9645 (Electronic)). https:\/\/doi.org\/10.1093\/eurheartj\/ehy114","DOI":"10.1093\/eurheartj\/ehy114"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04522-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04522-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04522-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:15:12Z","timestamp":1774883712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04522-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4522"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04522-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of The First School of Clinical Medicine, Southern Medical University, Guangzhou, China (Approval No. 202409808). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"508"}}